Skip to Main Content

Can Biogen pull itself back from the brink?

The company is ending 2021 with dismal sales of its treatment for Alzheimer’s disease and its stock depressed. Management is slashing the drug’s price and cutting expenses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment